CN115666510A - 用于治疗或预防病毒感染的氯法齐明组合物和方法 - Google Patents

用于治疗或预防病毒感染的氯法齐明组合物和方法 Download PDF

Info

Publication number
CN115666510A
CN115666510A CN202180031573.9A CN202180031573A CN115666510A CN 115666510 A CN115666510 A CN 115666510A CN 202180031573 A CN202180031573 A CN 202180031573A CN 115666510 A CN115666510 A CN 115666510A
Authority
CN
China
Prior art keywords
clofazimine
pharmaceutically acceptable
inhalable
excipient
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031573.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·霍夫曼
S·厄弗
J·J·小弗里曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of CN115666510A publication Critical patent/CN115666510A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202180031573.9A 2020-05-01 2021-04-30 用于治疗或预防病毒感染的氯法齐明组合物和方法 Pending CN115666510A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063018677P 2020-05-01 2020-05-01
US63/018,677 2020-05-01
PCT/US2021/030155 WO2021222740A1 (en) 2020-05-01 2021-04-30 Clofazimine composition and method for the treatment or prophylaxis of viral infections

Publications (1)

Publication Number Publication Date
CN115666510A true CN115666510A (zh) 2023-01-31

Family

ID=78332269

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180031573.9A Pending CN115666510A (zh) 2020-05-01 2021-04-30 用于治疗或预防病毒感染的氯法齐明组合物和方法

Country Status (9)

Country Link
US (1) US20230248722A1 (enExample)
EP (1) EP4142691A4 (enExample)
JP (1) JP2023524064A (enExample)
KR (1) KR20230005937A (enExample)
CN (1) CN115666510A (enExample)
AU (1) AU2021263580A1 (enExample)
BR (1) BR112022022081A2 (enExample)
CA (1) CA3177438A1 (enExample)
WO (1) WO2021222740A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
WO2025091042A1 (en) * 2023-10-27 2025-05-01 Mannkind Corporation Methods for treating non-tuberculous mycobacterial infection

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104027312A (zh) * 2009-11-02 2014-09-10 曼康公司 用于对药物组合物进行低温造粒的装置和方法
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN108853106A (zh) * 2017-05-09 2018-11-23 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
WO2019070693A1 (en) * 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE
WO2019110099A1 (en) * 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2020040818A1 (en) * 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071127B2 (en) * 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2929343T3 (es) 2008-06-13 2022-11-28 Mannkind Corp Inhalador de polvo seco accionado por aspiración para la administración de fármacos
AU2014228415B2 (en) * 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CA2943049A1 (en) * 2014-04-08 2015-10-15 Aradigm Corporation Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
CA2965258C (en) * 2014-10-24 2023-09-19 Redhill Biopharma Ltd. Therapy for inhibition of single-stranded rna virus replication

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104027312A (zh) * 2009-11-02 2014-09-10 曼康公司 用于对药物组合物进行低温造粒的装置和方法
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CN108853106A (zh) * 2017-05-09 2018-11-23 中国食品药品检定研究院 亚胺吩嗪类化合物作为狂犬病病毒抑制剂的用途
WO2019070693A1 (en) * 2017-10-02 2019-04-11 Board Of Regents, The University Of Texas System COMPOSITION FOR INHALING CLOFAZIMINE AND METHODS OF USE
WO2019110099A1 (en) * 2017-12-06 2019-06-13 Qrumpharma Inc. Inhalable clofazimine formulation
WO2020040818A1 (en) * 2018-08-23 2020-02-27 Qrumpharma Inc. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DUC DUY NGUYEN等: "Potentially highly potent drugs for 2019-nCoV", 《BIORXIV》, 5 February 2020 (2020-02-05), pages 1 - 13, XP055726990, DOI: 10.1101/2020.02.05.936013 *

Also Published As

Publication number Publication date
JP2023524064A (ja) 2023-06-08
EP4142691A4 (en) 2024-05-15
US20230248722A1 (en) 2023-08-10
AU2021263580A1 (en) 2022-11-24
EP4142691A1 (en) 2023-03-08
CA3177438A1 (en) 2021-11-04
KR20230005937A (ko) 2023-01-10
WO2021222740A1 (en) 2021-11-04
BR112022022081A2 (pt) 2022-12-13

Similar Documents

Publication Publication Date Title
WO2014066856A9 (en) Inhalable influenza vaccine compositions and methods
US20250228779A1 (en) Method and composition for treating pulmonary fibrosis
CN115666510A (zh) 用于治疗或预防病毒感染的氯法齐明组合物和方法
WO2015027848A1 (zh) 含有帕拉米韦和/或其衍生物制剂的给药方法
AU2022209720A1 (en) Methods and compositions for treating infections
JPH10500966A (ja) 経口吸入もしくは吹き込みにより投与する為の化合物、及び組成物
CA2813750A1 (en) Method for treating cystic fibrosis with inhaled denufosol
Thai et al. Development of inhalable formulations of anti-inflammatory drugs to potentially treat smoke inhalation injury in burn victims
HK40083799A (en) Clofazimine composition and method for the treatment or prophylaxis of viral infections
CN116916889A (zh) 用于肺高压领域的吸入式伊马替尼
CA3219943A1 (en) Dry powder formulations of tacrolimus for administration by inhalation once daily (qd)
TW201016215A (en) Compositions and uses of antiviral active pharmaceutical agents
JP6908523B2 (ja) ネブライザー用組成物
US20250288515A1 (en) Method and composition for treating lung diseases
HK40118869A (zh) 吸入用粉末及其生产方法
EP4304552A1 (en) Novel antiviral compositions and their use in therapy and in the treatment of viral infections
WO2025240845A1 (en) Method and composition for treating lung diseases
WO2023111930A1 (en) Powders for inhalation and production process thereof
HK40091740A (zh) 用於治疗、改善或预防微生物感染的制造产品和方法
CN114129546A (zh) 一种吸入用药物组合物
JP2024170686A (ja) 新規医薬
WO2015027847A2 (zh) 含有奥司他韦羧酸胍基类似体和/或其乙酯制剂的给药方法
CN104208060A (zh) 一种青霉素类抗生素的吸入制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083799

Country of ref document: HK